SCHEMBL1337628

SCHEMBL1337628

O=C(O)c1ccccc1C(=O)Nc1c(F)cc(-c2ccccc2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.55
AKR1C1 Q04828 1/20 0.55
POLB P06746 1/20 0.54
ALDH1A1 P00352 4/20 0.53
DHFR P00374 1/20 0.51
DHODH Q02127 7/20 0.51
MAPT P10636 2/20 0.50
ALPL P05186 1/20 0.49
ALPI P09923 1/20 0.49
GAA P10253 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
CYP1A2 P05177 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15928790 0.88 MEN1 (0.59) AKR1C2AKR1C1POLBALDH1A1DHODH
SCHEMBL1337701 0.87 DHODH (0.64) POLBALDH1A1DHODHMAPTGAA
SCHEMBL1335758 0.85 DHODH (0.55) POLBDHODHGAAL3MBTL1HTT
SCHEMBL1337760 0.85 DHODH (0.67) DHODHGAA
SCHEMBL1336640 0.84 DHODH (0.57) POLBDHODH
SCHEMBL1336906 0.83 DHODH (0.67) POLBALDH1A1DHODHMAPTGAA
SCHEMBL1336887 0.83 DHODH (0.72) DHODH
SCHEMBL1337736 0.83 DHODH (0.59) POLBALDH1A1DHODH
SCHEMBL1337185 0.82 KMT2A (0.52) POLBALDH1A1DHODHMAPTGAA
SCHEMBL1337800 0.82 DHODH (0.53) POLBALDH1A1DHODHGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR AKR1C2 160/4885AKR1C1 208/4885POLB 1683/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR AKR1C2 160/4885AKR1C1 208/4885POLB 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.